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ABSTRACT
The mechanism of telomerase re-activation in cancer had remained elusive 
until the discovery of frequent mutations in the promoter of the TERT gene that 
encodes the catalytic reverse transcriptase subunit of telomerase. We investigated 
the regulation of TERT expression in melanoma cell lines and our results show that 
promoter mutations render TERT expression dependent on MAPK activation due to 
oncogenic BRAF or NRAS mutations. Mutations in the TERT promoter create binding 
sites for ETS transcription factors. ETS1, expressed in melanoma cell lines, undergoes 
activating phosphorylation by ERK at Thr38 residue as a consequence of constitutively 
activated MAPK pathway. We demonstrate that ETS1 binds on the mutated TERT 
promoter leading to the re-expression of the gene. The inhibition of ETS1 resulted 
in reduced TERT expression. We provide evidence that the TERT promoter mutations 
provide a direct link between TERT expression and MAPK pathway activation due to 
BRAF or NRAS mutations via the transcription factor ETS1. 
INTRODUCTION
Melanoma arises from the malignant transformation 
of melanocytes that involves numerous genetic alterations 
affecting multiple signaling pathways including MAPK 
(Mitogen Activated Protein Kinase), PI3K (Phosphoinositide 
3-kinase), cAMP and cyclin D1/CDK4 [1]. The MAPK 
pathway plays a major role in melanoma proliferation 
and survival and is activated in the majority of melanoma 
tumors through mutations in BRAF and to some extent in 
NRAS. Mutations in BRAF constitute an early event and 
occur in over 80% of benign nevi; however, the sustained 
BRAF or NRAS expression in human melanocytes leads to 
oncogene-induced senescence [2, 3]. A critical step in the 
process of cellular immortalization remains the reactivation 
of telomerase. 
Telomerase, a ribonucleoprotein complex consisting 
of a catalytic subunit, reverse transcriptase (TERT) and 
an RNA component (TERC) acts canonically through 
maintenance of telomere homeostasis and chromosomal 
integrity [4]. TERT expression is tightly regulated, 
present during early embryonic development but remains 
repressed in most adult human somatic cells. However, 
over 90% of human cancers present reactivation of 
telomerase [5]. While benign and dysplastic nevi contain 
little or no telomerase, the majority of melanoma display 
substantial telomerase activity [6]. The mechanism for the 
cancer-specific reactivation of telomerase has remained 
unclear. The discovery of activating somatic mutations 
within the core promoter region of the TERT gene has 
provided an insight into the possible cause of telomerase 
re-expression in some cancer types. The initial TERT 
promoter mutation discovery came from a causal A > C 
germ line mutation at –57 bp (from ATG start site; Chr 
5:1,295,161 hg19 co-ordinate) in a large melanoma family. 
The TERT promoter mutations were also found to occur 
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as somatic alterations at a high frequency in melanoma 
tumors from unrelated patients [7, 8]. Subsequent studies 
showed occurrence of somatic TERT promoter mutations 
in a wide range of cancer types [9]. In melanoma, those 
somatic mutations have been associated with increased 
TERT expression, increased Breslow thickness, tumor 
ulceration, and poor disease-free and melanoma-specific 
survival [10, 11]. Another study suggested that TERT 
promoter mutations might constitute early secondary 
alterations [12]. The recurrent mutually exclusive 
C > T somatic mutations in the TERT promoter at –124 
(1,295,228) bp and –146 (1,295,250) bp, like familial 
mutation, result in the creation of a binding motif for 
the ETS (E26 transformation-specific) transcription 
factors with consequent tumor-specific increased TERT 
expression (Figure 1). The ETS family of transcription 
factors contains 28 members, which can be divided into 
13 subfamilies of one to three members. All proteins 
of the family share a conserved DNA binding domain 
that mediates monomeric binding to the ETS binding 
consensus sequence, consisting of an invariant GGA(A/T) 
core and, often, an extended sequence CCGGAA(A/T) 
[13, 14]. At least nine of the 28 ETS family proteins can 
be phosphorylated by ERK, and in eight of those cases that 
modification leads to increased transcriptional activation 
[15]. In melanoma the TERT promoter mutations 
occur together with BRAF and NRAS mutations more 
frequently than per chance, suggesting a link between 
TERT expression and MAPK pathway activation during 
immortalization of melanocytes via ETS proteins [10]. 
Several ETS members have been shown to bind to the 
sites created by mutations at the –124 and –146 positions 
in vitro. The transcription factors that have been shown 
to bind the sites include ETS1, ETS2, ELF1, ELF2, 
ETV6, p52 NF-κB and GABPA, however, no study has 
so far shown link between TERT expression and MAPK 
activation [16–18].
In this communication, we report that TERT 
expression is dependent of MAPK pathway activation 
only in melanoma cell lines carrying the TERT promoter 
mutations. Our data show expression of ETS1 and its 
phosphorylation in an ERK-dependent manner in all 
melanoma cell lines included in the study. We found 
that ETS1 binds to the TERT promoter with mutations 
but not with wild type sequence. ETS1 down-regulation 
partially inhibits TERT expression in cell lines with the 
TERT promoter mutations. Our study provides evidence 
of a direct link between TERT expression and MAPK 
pathway activation through the ETS1 transcription factor 
in melanoma cells carrying a TERT promoter mutation. 
RESULTS
To investigate a link between MAPK pathway 
activation and TERT expression in presence or absence 
of TERT promoter mutation, we performed experiments 
on nine melanoma cell lines with or without TERT, BRAF 
and NRAS mutations (Table 1). We first showed that 
normal human epidermal melanocytes (NHEM) did not 
express TERT; whereas, melanoma cell lines expressed 
different levels of TERT (Figure 2A). We observed no 
difference in the level of TERT protein in cells lines 
with and without promoter mutations. Both C8161 and 
UKRV-Mel21 cell lines also expressed TERT, despite 
the absence of promoter mutation. Similarly, there 
was no correlation between TERT expression level and 
heterozygosity or homozygosity of mutations at the –57, 
–124, –146 or –138_139 positions. Similar results were 
seen at the mRNA level with quantitative RT-PCR (data 
not shown). To evaluate the role of MAPK activation in 
TERT expression, four representative cell lines with (M74, 
WM266.4) or without (C8161, UKRV-Mel21) TERT 
promoter mutations were treated with the MEK inhibitor 
U0126. Western blots confirmed that U0126 inhibited 
ERK phosphorylation (Figure 2B). The effect of U0126 
on TERT mRNA level and protein were analyzed using 
real-time RT-PCR and western blotting, respectively. 
ERK inhibition was associated with a reduced TERT 
protein expression in cell lines carrying a TERT promoter 
mutation (M74, WM266.4) but not in the C8161 and 
UKRV-Mel21 cell lines, which do not carry such mutation 
(Figure 2B). This decrease in TERT expression was 
also observed at mRNA level (Figure 2C) suggesting 
an inhibition at the transcriptional level. No inhibition 
of TERT mRNA was seen upon U0126 treatment in 
C8161 or UKRV-Mel21 cell lines, confirming that TERT 
expression, in the absence of TERT promoter mutations, is 
independent of MEK/ERK. Moreover, similar results were 
obtained using another MEK inhibitor, trametinib, and the 
BRAF inhibitor vemurafenib in melanoma cell lines with 
BRAF mutations (Supplementary Figure S1). The data 
suggest that, at least in the investigated melanoma cell 
lines, TERT expression is dependent on the activation of 
the MAPK pathway in the presence of TERT promoter 
mutations. To identify the link between MAPK pathway 
activation and TERT transcription, we investigated the 
expression of different transcription factors of the ETS 
family in melanoma cell lines. We found that ETS1, which 
has previously been shown to be involved in development 
and invasion of melanoma, was expressed in melanocytes 
and in all melanoma cell lines that were investigated 
(Figure 2A and data not shown). Furthermore, ETS1 
was constitutively phosphorylated at threonine 38 in all 
melanoma cell lines. The phosphorylation at threonine, 
which activates ETS1, was dependent on ERK, shown by 
the activity of MEK inhibitor U0126 (Figure 2B). That 
result suggested that ETS1 could be the transcription 
factor linking the activation of the MAPK pathway to 
the expression of TERT in melanoma cell lines harboring 
TERT promoter mutations. 
To confirm this hypothesis, we first determined the 
effect of ETS1 over-expression on promoter activity of 
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the –124T mutant allele using luciferase reporter assays 
in the UKRV-Mel21 cell line. The first results from the 
assays showed that the reporter construct with the mutant 
allele showed higher promoter activity than the construct 
with wild type sequence (10-fold; t-test P 0.001); however, 
the addition of MEK inhibitor diminished the promoter 
activity in the construct with –124 C > T mutation 
(5- fold; t-test P 0.001; Figure 3A) and not in the construct 
without mutation. In a parallel experiment, the cells were 
co- transfected with ETS1 plasmid and reporter constructs 
with or without –124T promoter mutant allele. The results 
showed that ETS1 overexpression resulted in increased 
luciferase activity only with the reporter construct with 
the mutant allele, compared to the cells without mutant 
construct (11-fold; t-test P 0.002). Introduction of 
Trametinib, a MEK inhibitor, reversed the increase in 
promoter activity due the mutation in the presence of ETS1 
overexpression (3.2-fold; P < 0.001). Increased expression 
of ETS1 in cells transfected with ETS1 plasmids was 
confirmed with real-time PCR (Supplementary Figure S2). 
To evaluate the role of ETS1 on the endogenous 
TERT promoter, we used RNA interference to inhibit 
ETS1 expression in C8161, Colo829, M74, UKRV-Mel21 
and WM266.4 cell lines. Two different siRNAs reduced 
ETS1 protein level by more than 70% in all cell lines. This 
reduction was associated with a 50% to 60% decrease in 
TERT expression in Colo 829, M74 and WM266.4 cell 
lines carrying a mutant TERT allele but not in C8161 and 
UKRV-Mel21, which harbored wild-type TERT promoter 
(Figure 3B and Supplementary Figure S3). These results 
Figure 1: Distribution of mutations in the TERT promoter. The sporadic and germline mutations found in melanoma are shown 
in red below the TERT core promoter. The Ets/TCF consensus motifs created by mutations are underlined. The numbering above the 
sequence relates to the start codon (ATG) of TERT whereas the standardized positions of mutations on chromosome 5 are indicated in the 
boxes. The transcription start is indicated by an arrow.
Table 1: Mutational status of cell lines used in this study
Cell Line TERT promoter BRAF NRAS
NHEM WT WT WT
501Mel –124 C > T V600E WT
A375 –146 C > T V600E WT
C8161 WT WT Q61K
M74 –124 C > T V600E WT
Sk-Mel5 –138_139CC > TT V600E WT
Sk-Mel28 –57 A > C V600E WT
UKRV-Mel21 WT WT WT
WM266.4 –146 C > T V600D WT
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suggest that ETS1 is, at least in part, responsible for 
TERT expression in melanoma cell lines with a mutant 
TERT promoter. As GABPA has been previously shown 
to drive efficient TERT transcription in cell lines with the 
mutations [16], we tested whether inhibition of GABPA by 
RNA interference decreased TERT expression. Although, 
two different siRNAs reduced GABPA protein level by 
more than 70% in all cell lines, TERT expression remained 
unaffected (Figure 3B and Supplementary Figure S3). To 
confirm the ERK-ETS1-TERT connection, we combined 
ETS1/GABPA depletion with MEK inhibition. U0126 
inhibited ERK activation and reduced TERT expression, 
which was not further decreased by ETS1 or GABPA 
depletion (Figure 3C). To confirm that ETS1 is specifically 
recruited to the mutant TERT promoter, we performed 
ETS1 ChIP in M74 and WM266.4 cell lines both with 
TERT mutation, and C8161 and UKRV-Mel21 cell lines 
both without corresponding mutation. We showed that the 
TERT mutation induced a ten- to twelve-fold increase in 
ETS1 binding to the TERT promoter compared to the wild-
type allele (Figure 3D). Using ChIP assays, we could only 
detect weak binding of GABPA on the TERT promoter and 
it was not associated with promoter mutation. As a control, 
we evaluated the binding of GABPA to RACGAP1 and 
KIF20A promoters, two promoters that have recently been 
shown to be direct targets of GABPA [19]. We showed 
by ChIP assays that both promoters bound GABPA 
in melanoma cell lines (Supplementary Figure S2) 
demonstrating the efficacy of the assays to detect GABPA 
binding. These data demonstrate that ETS1 is selectively 
recruited to the mutant TERT allele in melanoma cell lines 
and induce an allele-specific activation of TERT. 
Figure 2: TERT expression is dependent on MAPK pathway activation. (A) Levels of TERT, phosphorylated ETS1 (pETS1), 
total ETS1 (ETS1), phosphorylated ERK (ppERK), total ERK (ERK) and actin were analyzed by western blotting in melanocytes (NHEM) 
and melanoma cell lines. The TERT promoter mutation status is indicated above the blots. (B) Melanoma cell lines were treated for 48 hrs 
with 3 μM, 10 μM of U0126 or DMSO (0). Levels of TERT, phosphorylated ERK (ppERK), total ERK (ERK), phosphorylated ETS1 
(pETS1), total ETS1 (ETS1) and actin were analyzed by western blotting. (C) Melanoma cell lines were treated for 24 hrs with 3 μM, 
10 μM of U0126 or DMSO (0). TERT mRNA levels were quantified by real-time PCR normalized to GAPDH. Values are mean ± s.d. of 
two experiments assayed in duplicate. The TERT promoter status is indicated underneath the bar-charts.
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Figure 3: ETS1 binds to the TERT promoter and control its expression. (A) Luciferase reporter constructs containing wild type 
TERT promoter sequence (WT) and sequence with mutant allele for the –124T mutant (-124T) were transfected in triplicate into UKRV-
Mel21 cell line with and without plasmids with ETS1 sequence. To determine the effect of MEK inhibitors, in parallel experiments cells 
after 6 hours of transcfection were treated with Trametinib. Cells were harvested 64 hours post transfection and reporter expression was 
analyzed using the Dual-Luciferase assay system. The constructs without either reporter gene did not show any activity and were used as 
controls. (B) Melanoma cell lines were transfected without any siRNA (-), a siRNA control (scr), siRNA targetting ETS1 (ets1a and ets1b) 
or GABPA (gabpa1 and gabpa2). After 72 hrs, levels of TERT, ETS1 GABPA and ACTIN were analyzed by Western Blotting. The TERT 
promoter status is indicated above the blots. (C) M74 melanoma cell line was transfected as above. 24 hrs later cells were treated with 
DMSO or 3 μM of U0126. After 48 hrs of treatment, levels of TERT, ETS1 GABPA and ACTIN were analyzed by Western Blotting. The 
TERT promoter status is indicated above the blots.  (D) Melanoma cell lines were formalin fixed and harvested. Chromatin precipitated by 
anti-ETS1, anti-GABPA or control IgG was reverse-cross-linked, and the obtained genomic fragments were quantified by real-time PCR. 
Values are presented as fold enrichment over the mean value of control IgG. Error bars represent standard deviations. 
Oncotarget53134www.impactjournals.com/oncotarget
DISCUSSION
Cellular immortalization is a multistep process 
and a major step in cancer development. It involves the 
sustained expression of telomerase, which gives cancer 
cells an infinite capability to divide through maintenance 
of telomeres. Although the reactivation of telomerase has 
a key role in the immortalization process, the mechanism 
underlying telomerase re-activation in cancers had remained 
elusive. However, the discovery of frequent mutations in 
the promoter of TERT highlighted a possible mechanism 
of catalytic subunit of reverse transcriptase expression 
in cancer cells. Functional studies have shown that the 
presence of TERT promoter mutations leads to failure of 
TERT repression upon cellular differentiation; in multiple 
cell lines, the mutant TERT promoter has been shown to 
cause massive epigenetic changes [20, 21]. 
However, the probable association between 
activation of TERT expression due to the promoter 
mutations and MAPK pathway activation has remain 
unexplored. Here, we show that the promoter mutations 
render the expression of TERT dependent on the activation 
the MAPK pathway. The MAPK pathway is activated 
mainly through oncogenic mutations of BRAF or NRAS, 
which are early events in melanoma development and 
in absence of other alterations lead to oncogene induced 
senescence. The acquisition of TERT promoter mutation 
in BRAF or NRAS mutated melanoma probably allows 
the re-expression of TERT leading to the immortalization 
process on path to melanoma development, together with 
other alterations such as inactivation of cyclin-dependent 
kinase inhibitor 2A (CDKN2A). TERT promoter 
mutations create novel binding sites for the ETS family 
of transcription factors. Several ETS proteins can be 
phosphorylated by ERK, and this modification activates 
their transcriptional activation [15]. We investigated the 
role of ETS1 transcription factor, which has previously 
been involved in the development and invasion of 
melanoma. ETS1 plays an important role in cancer 
progression due to its ability to activate the transcription 
of metastasis-, angiogenesis- and invasion-associated 
genes [22]. ETS1 gene expression has been associated 
with tumor progression in various tumors such as thyroid, 
pancreas, liver, lung and breast carcinomas, and melanoma 
[23]. ETS1 is expressed in melanoblasts in normal adult 
melanocytes and in transformed cells; however, its role in 
melanoma progression is unclear. ETS1 has been reported 
either as a valuable diagnostic⁄prognostic marker [24] 
or as molecule with no clear association with clinical 
outcome [25]. In the present study, we showed that ETS1 
is expressed in melanoma cell lines and is constitutively 
phosphorylated by ERK on Thr38 in melanoma cell lines 
due to the activation of the MAPK pathway associated 
with BRAF or NRAS mutations. Thr38 phosphorylation 
results in enhanced transactivation by preferential 
recruitment of the coactivators CREB binding protein 
(CBP) and p300 [26]. We demonstrated that ETS1 binds 
at the site created by the promoter mutations leading 
to TERT expression; the inhibition of ETS1 resulted 
in reduced TERT expression. These results are in 
accordance with recent data showing binding of ETS1 to 
TERT mutant promoter [17]. Amongst the several ETS1 
members that have been shown to bind at the sites created 
by the mutation at –124 position, GABPA has been shown 
to drive efficient TERT transcription [16]. In this study, 
we could detect the expression of GABPA in melanoma 
cell lines; however, its expression did not decrease 
upon MEK inhibition (Figure 3C and data not shown). 
This observation is in conformity with a previous study 
that compared MAPK specificity across all ETS family 
proteins and shows that GABPA has very few MAPK 
interacting domains for phosphorylation by ERK, JNK 
and p38α kinases [27]. We also showed that inhibition of 
GABPA by RNA interference does not decrease TERT 
expression and we could only detect weak binding of 
GABPA on the TERT promoter by ChIP assays, which did 
not associate with the promoter mutation. The reason for 
the discrepancy between our results and a previous study 
remains unclear [16]. GABPA could be in a complex 
preventing binding of the antibody by masking the 
epitope, or epigenetic modifications of the TERT promoter 
in our cells could prevent binding of the transcription 
factor [21]. Nevertheless, our experiments with siRNA 
targeting GABPA suggest that, at least in the cell lines 
tested, GABPA does not stimulate TERT expression 
even in the presence of a mutation at the –124 or –146 
positions. However, ETS1 inhibition induced only a partial 
reduction of TERT expression (Figure 3B) suggesting 
that other transcription factors may be involved in TERT 
expression in melanoma cells.
Our results have important implications for 
understanding the mechanism through which telomerase 
is reactivated in tumors cells. We provide evidence 
that TERT promoter mutations via ETS1 form a direct 
relationship between TERT expression and MAPK 
pathway activation through BRAF or NRAS mutations. 
This probably participates in cellular immortalization 
during melanoma development. 
MATERIALS AND METHODS
Cell culture and transfection
Normal neonatal human epidermal melanocytes 
(NHEM; Cascade Biologics, Nottinghamshire, United 
Kingdom) were cultured in medium 154 supplemented 
with human melanocyte growth supplement (Cascade 
Biologics). Human melanoma cell lines were cultured in 
DMEM or RPMI 1640 medium (Gibco, ThermoFisher 
Scientific) supplemented with 10% FBS, penicillin 
(100 Units/ml)/streptomycin (100 μg/ml) antibiotics, 
and 2 mM L-glutamine. All melanoma cell lines were 
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genotyped to verify their authenticity. siRNA were 
transfected using Lipofectamine RNAiMAX (Invitrogen) 
following the manufacturer instructions.  Sequences of the 
siRNA are in Supplementary Table S1.
Luciferase reporter gene constructs and 
expression vector
For reporter luciferase assays a 2.5 kbp region of 
TERT locus (chr5:1,294,815–1,297,313, hg19 coordinates) 
was amplified using genomic DNA. The amplified region 
included 2209 bp of promoter, followed by 219 bp of 
exon 1 and 60 bp of intron 1. The C > T mutation at –124 
position was generated using Quik-change site-directed 
mutagenesis kit (Invitrogen) and cloned into pGL4.10 
vector as described previously [28]. The ETS1 coding 
sequence in pENTR221 was obtained commercially and 
subcloned into pDEST26 Gateway expression vector.    
Luciferase reporter assay
For reporter assay, UKRV-Mel 21 cells were seeded 
in 12-well plates and transfected with Lipofectamine 
2000 (Invitrogen), 500 ng of reporter construct (WT or 
–124 C > T) and 50 ng of pRL-actin in triplicates. The 
pRL expressing renilla luciferase was used as an internal 
control for normalization of luminescence values. 
Promoter-less vector (pGL4.10[luc2]) and non-transfected 
cells were used as negative controls. The three plasmids 
(WT, –124 C > T and promoter-less vector) were assayed 
separately with or without MAPK inhibitor (Trametinib) 
and additionally with or without Ets-1 overexpression. 
For Ets1 overexpression, the corresponding cells were 
cotransfected with 100 ng of PDEST26-ETS1 expression 
plasmid that expressed human Ets1 coding sequence 
(GenBank: AY893450). To determine the effect of MEK 
inhibitor, the cells were treated with Trametinib dissolved 
in DMSO at a final concentration of 1 μM, 6 hours after 
transfection. As a control, DMSO was used in other batch 
of cells that were not treated with Trametinib. Cells were 
harvested 30 hours post transfection using 1x passive lysis 
buffer (Promega) and reporter expression was analyzed 
using the Dual-Luciferase assay system (Promega). 
The relative ratio of firefly luminescence to renilla 
luminescence was calculated to normalize the variations 
across samples. Statistical differences were determined 
using two-sided t-test in R.
Reverse transcription and real-time PCR
Total RNA was extracted from melanoma cell lines 
(RNeasy Mini Kit, QIAGEN) and treated with DNase 
(ThermoFisher Scientific); cDNA was prepared using the 
Themoscript kit (ThermoFisher Scientific). TERT mRNA 
level was quantified by real-time PCR using the Power SYBR 
Green kit (applied biosystems) normalized to GAPDH. 
Sequences of the primers are in Supplementary Table S1.
Protein expression and antibodies
Cells were lysed in RIPA and the proteins were 
subjected to an SDS-PAGE and western blot analysis 
was carried out according to standard protocols using 
the following antibodies: TERT (Santa Cruz technology 
and Thermo Fisher Scientific), PhosphoERK (Sigma), 
ERK (Millipore), PhosphoETS1 (Sigma), ETS1 (Bethyl) 
and GABPA (Santa Cruz technology). Antibodies 
were visualized using the SuperSignal West Pico 
Chemiluminescent Substrate (ThermoFisher Scientific).
ChIP
Cells were cultured in 10-cm plates to approximately 
80% confluence, and fixed with 1% formaldehyde. 
Chromatin Immunoprecipitation was carried out using 
the Pierce Agarose ChIP Kit (Thermo Fisher Scientific) 
following the manufacturer instructions. The genomic 
fragments were quantified by real-time PCR using the 
Power SYBR Green kit (applied biosystems) and primers 
surrounding the –124 and –146 TERT promoter mutations 
(Supplementary Table S1). Primers for the RACGAP1 and 
KIF20A promoters have been described previously [19]. 
The antibodies used included, ETS1, GABPA (Santa Cruz 
technology) and rabbit IgG control (Abcam). 
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